8-KCorporate ChangesExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Bylaw Amendment (Aug 21, 2018)

Filed August 21, 2018For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) filed an 8-K on August 21, 2018, to report amendments to its By-Laws, effective August 16, 2018. These changes are administrative in nature, focusing on clarifying the roles and responsibilities of corporate officers, particularly the Chief Executive Officer and President. The Board of Directors has updated the By-Laws to better define the delegation of appointment and removal powers for certain officers to the CEO, and to generally clarify the authority and duties of Company officers. These amendments do not appear to represent a significant shift in the company's strategic direction or financial operations, but rather an internal housekeeping measure to ensure operational clarity and efficiency within the executive structure.

Key Highlights

  • 1Quest Diagnostics amended and restated its By-Laws on August 16, 2018.
  • 2The amendments are effective immediately as of the Board's decision.
  • 3Key changes involve updating the roles of the Chief Executive Officer and President.
  • 4Clarification provided on the Board's authority to delegate officer appointment/removal powers to the CEO.
  • 5The By-Laws were updated to reflect current officer titles.
  • 6General clarification of officer authority and responsibilities has been implemented.
  • 7The amended By-Laws are filed as an exhibit to the 8-K.

Frequently Asked Questions

The primary purpose is to update and clarify the roles, responsibilities, and appointment/removal authorities of the company's officers, particularly the CEO and President, to enhance internal governance and operational clarity.

Based on the filing, these amendments appear to be primarily administrative and internal in nature, focusing on corporate governance and officer duties. They do not suggest a change in the company's strategic direction or immediate financial outlook.

The full text of the Amended and Restated By-laws of Quest Diagnostics Incorporated, as amended effective August 16, 2018, is filed as Exhibit 3.1 to this Current Report on Form 8-K.

The filing specifically addresses amendments to the By-Laws concerning officer roles and responsibilities. It does not indicate any changes to the Board of Directors' composition or broader governance structure beyond the clarification of delegated authority to the CEO.